Nasdaq: DMAA
Drugs Made In America Acquisition Corp. (DMAA)
Drugs Made In America Acquisition Corp. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker DMAA. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.
Key facts
- Ticker symbol
- DMAA
- Exchange
- Nasdaq
- SEC CIK
- 2028614
- Official filings
- SEC EDGAR
Research DMAA
- Profile — Business description, headquarters, subsidiaries and corporate identifiers.
- Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
- SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
- Stock Analysis — Price chart, returns, technical indicators and related companies.
- News — Latest headlines and press coverage.
- Material Contracts — Material agreements filed as exhibits to SEC reports.
- Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
- Peer Comparison — Side-by-side financial ratios against industry peers.
Frequently asked questions
What is Drugs Made In America Acquisition Corp.'s stock ticker?
Drugs Made In America Acquisition Corp. trades under the ticker symbol DMAA on Nasdaq. Its SEC Central Index Key (CIK) is 2028614.
Where can I read Drugs Made In America Acquisition Corp.'s SEC filings?
The DMAA SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Drugs Made In America Acquisition Corp. has filed, with AI analysis. The original documents are also on SEC EDGAR.
How can I analyze DMAA's financial statements?
The DMAA Financials page shows Drugs Made In America Acquisition Corp.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.
How does DMAA compare with its peers and the market?
The DMAA Peer Comparison page lines Drugs Made In America Acquisition Corp. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.
For information only — not investment advice.